Applied Therapeutics to Present at the UBS Biopharma Conference 2023
02 Novembre 2023 - 12:00PM
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage
biopharmaceutical company developing a pipeline of novel drug
candidates against validated molecular targets in indications of
high unmet medical need, today announced that it will present at
the UBS Biopharma Conference 2023 on Thursday, November 9, 2023 at
2:00 p.m. ET in Miami, Florida.
A live webcast for this event will be accessible
on the Events page under the Investor Relations section of the
Applied Therapeutics website at www.appliedtherapeutics.com. A
replay of the webcast will be archived on the Company’s website for
90 days following the event.
About Applied Therapeutics
Applied Therapeutics is a clinical-stage biopharmaceutical
company developing a pipeline of novel drug candidates against
validated molecular targets in indications of high unmet medical
need. The Company’s lead drug candidate, govorestat, is a novel
central nervous system penetrant Aldose Reductase Inhibitor (ARI)
for the treatment of CNS rare metabolic diseases, including
Galactosemia, SORD Deficiency, and PMM2-CDG. The Company is also
developing AT-001, a novel potent ARI, for the treatment of
Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart.
The preclinical pipeline also includes AT-003, an ARI designed to
cross through the back of the eye when dosed orally, for the
treatment of Diabetic Retinopathy.
To learn more, please visit www.appliedtherapeutics.com and
follow the company on Twitter @Applied_Tx.
Contacts
Investors:
Maeve Conneighton (212) 600-1902
appliedtherapeutics@argotpartners.com
Media:
media@appliedtherapeutics.com
Applied Therapeutics, Inc.
Applied Therapeutics (NASDAQ:APLT)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Applied Therapeutics (NASDAQ:APLT)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024